Report Phase 2b clinical trial data for South Africa
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2021
- Due
- 31 Mar 2021
- Delivered
- 28 Jan 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Preliminary Data Expected Early Q1”
What we found
Evidence strength A What the grades mean
Novavax reported the Phase 2b clinical trial data for South Africa on January 28, 2021, which falls within the early first quarter deadline.
-
A Novavax Inc. 8-K filed 2021-05-11
“Reported final efficacy analysis from UK Phase 3 trial and complete analysis from South Africa Phase 2b trial, expanding upon previously reported interim results” ✓ confirmed on the page
Market reaction: the shares moved -22.8% against the S&P 500 over the three sessions around the disclosure (10 May 2021 to 13 May 2021). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- South Africa Phase 2b clinical trial data
- Where
- South Africa
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Novavax Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-NVAX-021473 · Corrections policy